查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000740

癌症惡病質市場：2026-2032年全球市場預測（按治療方法、給藥途徑、年齡層、性別、分銷管道和最終用戶分類）

Cancer Cachexia Market by Therapy Type, Route Of Administration, Age Group, Gender, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症惡病質市場價值將達到 23.7 億美元，到 2026 年將成長到 25 億美元，到 2032 年將達到 41 億美元，複合年成長率為 8.14%。

主要市場統計數據
基準年 2025 23.7億美元
預計年份：2026年 25億美元
預測年份 2032 41億美元
複合年成長率 (%) 8.14%

一個簡潔而權威的癌症惡病質框架，強調了臨床複雜性、不斷發展的科學以及整合治療和護理策略的必要性。

癌症惡病質仍然是一種複雜的、多因素的症候群，它會損害患者的抵抗力，使腫瘤治療更加複雜，並給商業性和臨床相關人員帶來挑戰。目前的臨床重點包括早期識別惡病質、整合多學科管理以及使治療策略與以患者為中心的結果一致。最新的臨床實踐指南強調，需要協調營養支持、標靶治療和基於症狀的護理，以維持患者的功能和生活品質為整體目標。

新的科學進步、重新設計的護理路徑以及數位化護理的提供，正在重新定義惡病質治療的發展和商業模式。

在科學、臨床和商業力量的共同作用下，癌症惡病質的治療模式正經歷一場變革。基礎科學的進步加深了我們對發炎介質、代謝重再程式化和食慾調節路徑的理解，加速了標靶藥物的研發進程，並重新激發了人們對促效劑和食慾刺激藥物的興趣。同時，臨床醫生正在採用早期篩檢和評估框架，並將臨床路徑從被動的危機管理轉向積極的支持性治療，從而催生了對能夠及時進行早期療育的產品和服務的需求。

2025 年的價格政策變化將重組採購、生產策略和支付方審查，改變與惡病質相關的治療方法和用品的商業計劃。

2025年新定價政策的實施進一步增加了癌症惡病質相關治療方法、醫療設備和營養產品的供應鏈和採購計畫的複雜性。跨境交易成本的上升引發了人們對籌資策略、定價結構和分銷網路韌性的擔憂。採購團隊和業務部門負責人必須權衡投入成本的即時影響與長期決策，例如在地化生產、重新談判合約和庫存策略，以確保患者能夠獲得所需藥物，同時維持利潤率。

透過整合治療方法、分銷管道、管理途徑、醫療保健環境和患者人口統計資訊的多面向細分框架，制定個人化策略。

精細的細分觀點揭示了臨床需求與給藥方式和商業性機會的交匯點。根據治療類型，相關人員必須考慮醫療設備、營養補充劑和藥品。藥品類別可進一步細分為作用機轉和臨床目標不同的藥物，例如阿那莫林、食慾促效劑和皮質類固醇。這種連續性要求採用差異化的證據策略。醫療設備和營養補充劑通常依賴功能性益處和藥物依從性的實際應用，而藥品則通常進行對照臨床試驗以確定其療效和安全性。

美洲、歐洲、中東和非洲以及亞太地區的區域性因素，推動了惡病質解決方案的在地化取得、證據產生和供應鏈彈性策略。

區域趨勢對臨床實踐、報銷途徑和供應鏈設計有顯著影響，因此領導者需要將這些區域趨勢轉化為可執行的計劃。在美洲，醫療保健系統內存在多種支付模式，其中真實世界證據和結果對報銷決策的影響尤其重要。這種環境有利於那些具有可證實的功能優勢和經濟價值分析的產品，這些產品能夠吸引綜合醫療網路和私人保險公司的注意。在該地區運營的製造商通常需要在國家監管要求與採購和分銷基礎設施的區域差異之間尋求平衡。

製藥、營養、醫療設備、生物技術和服務供應商之間的競爭與合作動態，正在為一體化解決方案和夥伴關係主導的規模化發展鋪平道路。

競爭動態中既有成熟的製藥公司，也有專業的醫療設備製造商、營養品相關企業和新興的生技公司，它們各自為惡病質治療生態系統貢獻獨特的優勢。製藥公司致力於研發標靶分子，旨在刺激食慾、促進合成代謝和調節發炎反應，並在製定對照試驗和與監管機構合作方面發揮主導作用。營養素和膳食補充劑供應商則透過專注於熱量和蛋白質的輸送、微量營養素的最佳化以及藥物依從性支持技術，為藥物治療提供補充，從而改善整體治療效果。

領導者可採取的策略重點是協調臨床證據、供應鏈韌性、數位化和跨部門夥伴關係，以加速產生影響力。

產業領導者應進行有針對性的投資，積極降低商業性和營運風險，同時使科學預期與實際應用模式相符。首先，應優先利用標準化篩檢通訊協定和遠端監測工具，儘早識別並納入患者群體，以便更早展現臨床效益並最佳化治療路徑。同時，應設計包含功能性結果和患者報告結果（除傳統終點外）的臨床項目，以滿足支付方的期望並支持報銷談判。

為了支持實際見解，我們採用嚴格的混合方法研究途徑，結合文獻整合、相關人員訪談、案例研究和情境分析。

本研究整合了同行評審的臨床文獻、監管指南、真實世界數據（REW）舉措以及與臨床醫生、支付方和供應鏈專家的相關人員訪談，構建了惡病質生態系統的全面圖景。資料收集強調多資訊來源三角驗證，以檢驗趨勢並確保研究結果既反映臨床實際情況又符合商業性限制。除了定性見解外，關於產品上市、分銷模式和循證策略的案例研究為市場准入和業務拓展提供了實踐經驗。

簡潔扼要的結論強調了整合證據、交付模式和夥伴關係以產生持久影響的臨床緊迫性和策略必要性。

癌症惡病質帶來沉重的臨床負擔，但也為創新、全面的解決方案提供了絕佳的機會，這些解決方案融合了藥物治療、營養治療、醫療設備和服務要素。科學進步、醫療服務模式的變革以及商業性模式的調整，為相關人員重新定義以功能性結果和病患體驗為優先的治療策略創造了有利條件。同時，政策和定價趨勢的變化要求制定周密的產業計畫，以維持醫療服務的可及性並確保永續的商業化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法的癌症惡病質市場

  • 藥物治療
    • 黃體素
    • 皮質類固醇
    • 非類固醇消炎劑
  • 聯合治療
    • 藥物治療與營養治療相結合
    • 多方面惡病質管理方案
  • 營養支持

第9章：癌症惡病質市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第10章：癌症惡病質市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第11章：癌症惡病質市場：性別

  • 男性
  • 女士

第12章：癌症惡病質市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：癌症惡病質市場：依最終用戶分類

  • 門診治療
  • 居家照護
  • 醫院

第14章：癌症惡病質市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：癌症惡病質市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症惡病質市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國癌症惡病質市場

第18章：中國癌症惡病質市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AAVogen Inc.
  • Actimed Therapeutics Ltd.
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Artelo Biosciences Inc.
  • AVEO Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Fresenius Kabi AG
  • Green Cross Wellbeing Corporation
  • Helsinn Healthcare SA
  • INOVIO Pharmaceuticals Inc.
  • Mankind Pharma Ltd.
  • Merck & Co. Inc.
  • MetaFines Co., Ltd.
  • NeuBase Therapeutics, Inc.
  • NGM Biopharmaceuticals Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Tetra Bio-Pharma
Product Code: MRR-02026C4C92B4

The Cancer Cachexia Market was valued at USD 2.37 billion in 2025 and is projected to grow to USD 2.50 billion in 2026, with a CAGR of 8.14%, reaching USD 4.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.37 billion
Estimated Year [2026] USD 2.50 billion
Forecast Year [2032] USD 4.10 billion
CAGR (%) 8.14%

A concise and authoritative framing of cancer cachexia that clarifies clinical complexity, evolving science, and the need for integrated therapeutic and care delivery strategies

Cancer cachexia remains a complex, multifactorial syndrome that undermines patient resilience, complicates oncologic care, and challenges commercial and clinical stakeholders alike. The prevailing clinical imperative is to recognize cachexia early, integrate multidisciplinary management, and align therapeutic strategies with patient-centered outcomes. Recent clinical practice guidelines emphasize the need for coordinated nutritional support, targeted pharmacologic interventions, and symptom-directed care that collectively aim to preserve function and quality of life.

At the same time, research into pathophysiology has clarified contributing mechanisms, including systemic inflammation, metabolic dysregulation, and neurohormonal signaling. These advances have driven renewed interest in developing agents that modulate appetite, counteract catabolism, or intervene in signaling pathways associated with muscle wasting. Consequently, stakeholders from device makers to supplement developers and pharmaceutical sponsors are re-evaluating their roles in an ecosystem that demands integrated solutions across care settings and delivery models.

Therefore, the introduction here sets the stage for understanding how evolving science, shifting care delivery practices, and new commercial imperatives intersect to shape opportunities and risks. With that context, subsequent sections explore transformative landscape shifts, the implications of changing tariff dynamics, actionable segmentation and regional insights, and clear recommendations for industry leaders seeking to move from insight to impact.

Emerging scientific breakthroughs, care pathway redesigns, and digital care delivery are converging to redefine therapeutic development and commercial models for cachexia management

The landscape for cancer cachexia is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Advances in basic science have expanded understanding of inflammatory mediators, metabolic reprogramming, and appetite-regulating pathways, which in turn have catalyzed targeted drug development programs and renewed interest in anabolic and appetite-stimulating agents. Concurrently, clinicians are adopting earlier screening and assessment frameworks, shifting the clinical pathway from reactive crisis management to proactive supportive care, and thereby creating demand for products and services that fit earlier intervention windows.

In parallel, technology-enabled care models and telehealth have accelerated, enabling more frequent monitoring of weight, functional capacity, and nutritional intake outside traditional clinic visits. These models facilitate longitudinal data collection and patient engagement, improving the feasibility of multidimensional interventions that combine pharmacotherapy, nutrition, and physical rehabilitation. Moreover, regulators and payers are increasingly receptive to evidence demonstrating functional benefit and patient-reported outcomes, which raises the bar for clinical development while also opening new reimbursement levers for therapies that show meaningful improvement in quality of life.

Commercial dynamics are also shifting. Manufacturers and service providers must adapt to channel diversification as patients and caregivers seek convenient access points for supportive care products and supplements. At the same time, strategic partnerships between pharmaceutical sponsors, nutritional companies, and device manufacturers are emerging to offer bundled solutions that address both biological drivers and supportive needs. Thus, the transformative shifts are not isolated to science or care delivery; they span the full value chain, demanding integrated strategies that align clinical evidence, distribution capabilities, and payer engagement.

Shifts in 2025 tariff policy are reshaping procurement, manufacturing strategies, and payer scrutiny in ways that alter commercial planning for cachexia-related therapies and supplies

The introduction of new tariff policies in 2025 has introduced additional complexity to supply chain and procurement planning for therapies, medical devices, and nutritional products relevant to cancer cachexia. Increased cross-border trade costs raise questions about sourcing strategies, pricing structures, and the resilience of distribution networks. Procurement teams and commercial leaders must weigh the immediate implications for input costs against longer-term decisions about manufacturing localization, contract renegotiations, and inventory strategies that preserve patient access while protecting margins.

Consequently, organizations are examining nearshoring and dual-sourcing approaches to mitigate exposure to tariff volatility, while also reassessing contractual terms with distributors and wholesalers to allocate risk more equitably across the supply chain. In turn, these shifts influence go-to-market tactics, as price-sensitive channels may demand different promotional strategies and support models to maintain uptake. For therapeutics that rely on cold chain logistics or specialized packaging, the incremental tariff burden compounds existing operational complexity and encourages investments in process efficiency and supply chain visibility.

Finally, stakeholders should anticipate that tariff-driven cost pressures will accelerate demand for evidence of economic value and real-world effectiveness. Payers and health systems will scrutinize claims of improved function and reduced resource utilization more closely when acquisition costs rise. Therefore, organizations that proactively adapt procurement, manufacturing, and value demonstration strategies will be better positioned to sustain access and commercial momentum in the face of changing trade policy dynamics.

A multidimensional segmentation framework that aligns treatment modalities, distribution channels, administration routes, care settings, and patient demographics to inform tailored strategies

A nuanced segmentation view reveals where clinical need intersects with delivery modalities and commercial opportunity. Based on treatment type, stakeholders must consider medical devices, nutraceuticals and supplements, and pharmaceuticals, with the pharmaceutical category subdividing into agents such as anamorelin, appetite stimulants, and corticosteroids that address distinct mechanisms and clinical objectives. This continuum requires differentiated evidence strategies: medical devices and supplements often rely on pragmatic, real-world demonstrations of functional benefit and adherence, while pharmaceuticals typically pursue controlled trials to establish efficacy and safety profiles.

Distribution channel segmentation highlights how access pathways shape adoption and patient experience, with hospital pharmacies, online pharmacies, and retail pharmacies each offering different touchpoints for dosing support, counseling, and follow-up. Channel choice influences formulary placement, visibility to prescribers, and the design of patient support programs. Route of administration segmentation underscores clinical and operational trade-offs between injectable and oral therapies, noting that injectables further divide into intravenous and subcutaneous options; injectables may demand facility resources and cold chain logistics, while oral options often emphasize adherence support and convenience for outpatient and home-based care.

End user segmentation across ambulatory care, home care, and hospitals clarifies where interventions must integrate with care teams and workflows. Home care settings increasingly require simplified regimens and robust remote monitoring, whereas hospital-based interventions can leverage multidisciplinary teams and intensive supportive services. Patient demographic segmentation by age group and gender further refines targeting, as adult, geriatric, and pediatric cohorts have unique physiological responses and care considerations, and differences between female and male patients can influence symptom presentation, dosing considerations, and support needs. Taken together, these segments create a multidimensional landscape in which product design, clinical evidence generation, and commercial tactics must align to the specific demands of each therapy-channel-route-user-patient intersection.

Regional considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific drive tailored access, evidence generation, and supply chain resilience strategies for cachexia solutions

Regional dynamics materially affect clinical practice, reimbursement pathways, and supply chain design, and leaders must translate regional patterns into actionable plans. In the Americas, healthcare systems demonstrate a range of payer models and an emphasis on real-world evidence and outcomes that drive reimbursement decisions; this environment favors products backed by demonstrable functional gains and economic value analyses that resonate with integrated delivery networks and private payers. Manufacturers operating here often balance national regulatory expectations with regional differences in procurement and distribution infrastructure.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and payer systems requires adaptive market access strategies, with local evidence generation and stakeholder engagement playing a pivotal role in uptake. Pricing pressures and budget constraints in parts of Europe emphasize cost-effectiveness and patient benefit, whereas some Middle Eastern and African markets present opportunities for partnership-driven program deployment and capacity building to support therapy delivery. Across this region, tailored approaches to channel partnerships and local manufacturing or sourcing can enhance responsiveness and affordability.

In Asia-Pacific, diverse economic contexts and rapidly evolving healthcare investment are reshaping demand for integrated cachexia solutions. Some markets in the region prioritize rapid adoption of digital health and home-based care models, enabling scalable remote monitoring and patient support programs. Elsewhere, fragmented access and variable reimbursement pathways necessitate focused pilot programs and strong clinical advocacy to demonstrate value. Across all regions, strategic alignment of regulatory strategy, supply chain resilience, and culturally attuned patient engagement will determine which products gain sustainable traction.

Competitive and collaborative dynamics across pharmaceutical, nutritional, device, biotech, and service providers reveal pathways for integrated solutions and partnership-driven scale

Competitive dynamics reflect a mix of established pharmaceutical sponsors, specialty device manufacturers, nutritional companies, and emerging biotechs, each bringing distinct capabilities to the cachexia ecosystem. Pharmaceutical sponsors advance targeted molecules aimed at appetite stimulation, anabolic support, and anti-inflammatory modulation, and they often lead in controlled-evidence development and engagement with regulatory authorities. Nutritional companies and supplement providers complement pharmacologic approaches by focusing on caloric and protein delivery, micronutrient optimization, and adherence-support technologies that can enhance overall therapeutic outcomes.

Device manufacturers contribute dosing platforms, monitoring tools, and supportive technologies that facilitate administration and longitudinal assessment of functional endpoints. Emerging biotechs and clinical-stage developers are also introducing innovative modalities that expand the therapeutic toolkit and may partner with larger organizations to scale development and commercialization. Strategic alliances between these stakeholder groups are common, as combined offerings can address multiple drivers of cachexia and present a more compelling value proposition to clinicians, payers, and patients.

Finally, service providers that specialize in home infusion, nutritional counseling, and remote monitoring play a vital role in adoption by reducing barriers to use and improving adherence. These providers often function as important distribution and support partners, enabling broader access and generating real-world evidence that reinforces clinical value claims. For organizations evaluating competition and potential collaborators, the landscape favors partners who can demonstrate integrated capabilities across evidence generation, delivery logistics, and patient-centric support.

Actionable strategic priorities for leaders to align clinical evidence, supply chain resilience, digital enablement, and cross-sector partnerships to accelerate impact

Industry leaders should pursue targeted investments that align scientific promise with pragmatic delivery models while actively mitigating commercial and operational risk. First, prioritize early identification and engagement of patient cohorts through standardized screening protocols and remote monitoring tools so clinical benefit can be demonstrated earlier and care pathways can be optimized. Parallel to this, design clinical programs that incorporate functional and patient-reported outcomes alongside traditional endpoints to meet payer expectations and to support reimbursement discussions.

Second, build flexible supply chain strategies that include alternative sourcing, nearshoring where appropriate, and collaborations with channel partners to preserve access amid tariff and logistical pressures. Simultaneously, cultivate partnerships that bring together pharmaceuticals, nutrition, and device capabilities into bundled offerings to simplify decision-making for clinicians and payers. Third, invest in digital health and patient support platforms that enhance adherence, capture real-world effectiveness data, and enable value-based contracting conversations. Such investments will also improve patient engagement and long-term outcomes.

Finally, adopt a regionalized go-to-market playbook that adapts evidence generation, pricing, and distribution tactics to local payer requirements and care models. By integrating these approaches-clinical relevance, supply chain resilience, cross-sector partnerships, digital enablement, and regional tailoring-organizations can convert scientific advances into sustainable patient impact and commercial success.

A rigorous mixed-methods research approach combining literature synthesis, stakeholder interviews, case studies, and scenario analysis to support actionable insights

This research synthesizes peer-reviewed clinical literature, regulatory guidance, real-world evidence initiatives, and stakeholder interviews with clinicians, payers, and supply chain experts to develop a comprehensive view of the cachexia ecosystem. Data collection emphasized triangulation across multiple sources to validate trends and to ensure findings reflect both clinical realities and commercial constraints. Qualitative inputs were supplemented by case studies of product launches, distribution models, and evidence-generation strategies to illuminate practical lessons for market entry and scale.

Analytical methods included thematic synthesis of scientific developments, scenario analysis for supply chain and tariff impacts, and segmentation mapping to align therapeutic approaches with channels, routes, care settings, and patient cohorts. Stakeholder interviews probed clinical adoption drivers, reimbursement expectations, and operational barriers, while secondary literature provided context on evolving mechanisms of disease and therapeutic modalities. Throughout, emphasis was placed on transparency of source types and on clearly distinguishing well-established evidence from emerging hypotheses to guide pragmatic decision-making.

A succinct conclusion that underscores the clinical urgency and strategic imperative to integrate evidence, delivery models, and partnerships for durable impact

Cancer cachexia presents both a significant clinical burden and a compelling opportunity for innovative, integrated solutions that combine pharmacologic, nutritional, device, and service elements. The convergence of scientific progress, care delivery transformation, and commercial adaptation creates a window for stakeholders to reimagine therapeutic strategies that prioritize functional outcomes and patient experience. At the same time, policy shifts and tariff dynamics require careful operational planning to preserve access and enable sustainable commercialization.

In conclusion, success in addressing cachexia will rest on the ability of organizations to align rigorous evidence generation with adaptable delivery models, to form strategic collaborations across sectors, and to engage payers with robust demonstrations of functional and economic value. Those who move decisively to integrate clinical, commercial, and operational strategies will be best positioned to deliver measurable benefits to patients and durable returns for investors and partners.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Cachexia Market, by Therapy Type

  • 8.1. Pharmacological Interventions
    • 8.1.1. Progestogens
    • 8.1.2. Corticosteroids
    • 8.1.3. Nonsteroidal Anti-inflammatory Drugs
  • 8.2. Combination Approaches
    • 8.2.1. Drug And Nutrition Combinations
    • 8.2.2. Multimodal Cachexia Management Programs
  • 8.3. Nutritional Support

9. Cancer Cachexia Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral

10. Cancer Cachexia Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Cancer Cachexia Market, by Gender

  • 11.1. Male
  • 11.2. Female

12. Cancer Cachexia Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Cancer Cachexia Market, by End User

  • 13.1. Ambulatory Care
  • 13.2. Home Care
  • 13.3. Hospitals

14. Cancer Cachexia Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Cachexia Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Cachexia Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Cachexia Market

18. China Cancer Cachexia Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AAVogen Inc.
  • 19.6. Actimed Therapeutics Ltd.
  • 19.7. Aeterna Zentaris Inc.
  • 19.8. Aphios Corporation
  • 19.9. Artelo Biosciences Inc.
  • 19.10. AVEO Pharmaceuticals Inc.
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Bristol-Myers Squibb Company
  • 19.13. Fresenius Kabi AG
  • 19.14. Green Cross Wellbeing Corporation
  • 19.15. Helsinn Healthcare SA
  • 19.16. INOVIO Pharmaceuticals Inc.
  • 19.17. Mankind Pharma Ltd.
  • 19.18. Merck & Co. Inc.
  • 19.19. MetaFines Co., Ltd.
  • 19.20. NeuBase Therapeutics, Inc.
  • 19.21. NGM Biopharmaceuticals Inc.
  • 19.22. Ono Pharmaceutical Co., Ltd.
  • 19.23. Pfizer Inc.
  • 19.24. Tetra Bio-Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PROGESTOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PROGESTOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PROGESTOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DRUG AND NUTRITION COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DRUG AND NUTRITION COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DRUG AND NUTRITION COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MULTIMODAL CACHEXIA MANAGEMENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MULTIMODAL CACHEXIA MANAGEMENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MULTIMODAL CACHEXIA MANAGEMENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CANCER CACHEXIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CANCER CACHEXIA MARKET SIZE, BY PHARMACOLOGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CANCER CACHEXIA MARKET SIZE, BY COMBINATION APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)